Overview

Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.

Status:
Completed
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of TAS5315 in combination with methotrexate in a 12 week or 36 week in participants with rheumatoid arthritis with inadequate response to methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Treatments:
Methotrexate